Kineta Inc., of Seattle, reported data demonstrating that KIN 1148 enhances the efficacy of existing influenza vaccines in animal models through a balanced immune response. Additionally, enhanced effectiveness with KIN 1148 was achieved while using lower vaccine doses. Data were presented at the World Vaccine Congress in Washington.